<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[PrIME Biologics Private Limited 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=23409></link><description><![CDATA[PrIME Biologics Private Limited 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sat, 16 May 2026 01:01:38 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><language>ko-KR</language><item><title><![CDATA[PrIME Biologics Announces SGD16M in Equity Funding Led by Xeraya Capital]]></title><link>https://www.newswire.co.kr/newsRead.php?no=769203</link><description><![CDATA[SINGAPORE--(Business Wire/Korea Newswire)--PrIME Biologics Private Limited today announced investments from Xeraya Capital Labuan Ltd via its affiliate, Pulau Manukan Ventures Labuan Ltd, and JP Asia Prime Capital Pte Ltd.  This investment will enable PrIME Biologics to establish the first human blood plasma fractionation plant in South East Asia at its Singapore cGMP facility using its ...]]></description><pubDate>Wed, 08 Oct 2014 13:45:00 +0900</pubDate></item><item><title><![CDATA[PrIME 바이오로직스, 세라야 캐피털 주도로 1600만 싱가포르달러 규모 사모펀딩 발표]]></title><link>https://www.newswire.co.kr/newsRead.php?no=769205</link><description><![CDATA[싱가포르--(Business Wire/뉴스와이어)--PrIME 바이오로직스(PrIME Biologics Private Limited)는 오늘 세라야 캐피털 라부안(Xeraya Capital Labuan Ltd)의 자회사 풀라우 마누칸 벤처스 라부안(Pulau Manukan Ventures Labuan Ltd)과 JP 아시아 프라임 캐피털(JP Asia Prime Capital Pte Ltd.)을 통해 세라얀 캐피털로부터의 투자를 발표했다.  이번 투자는 PrIME 바이오로직스가 동남아시아 최초로, 특허 받은 P...]]></description><pubDate>Wed, 08 Oct 2014 13:45:00 +0900</pubDate></item></channel></rss>